Tumor Biology

, Volume 37, Issue 7, pp 9919–9930 | Cite as

SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer

Original Article


Sushi domain containing 2 (SUSD2) is type I membrane protein containing domains inherent to adhesion molecules. There have been few reported studies on SUSD2, and they have mainly focused on breast cancer, colon cancer, and HeLa cells. However, the expression and function of SUSD2 in other cancers remain unclear. In the present study, we conducted an integrated bioinformatics analysis based on the array data from the GEO database and found a significant downregulation of SUSD2 in renal cell carcinoma (RCC) and lung cancer. Western blotting and quantitative RT-PCR (qRT-PCR) confirmed that SUSD2 was frequently decreased in RCC and lung cancer tissues compared with the corresponding levels in normal adjacent tissues. The restoration of SUSD2 expression inhibited the proliferation and clonogenicity of RCC and lung cancer cells, whereas the knockdown of SUSD2 promoted A549 cell growth. Our findings suggested that SUSD2 functions as a tumor suppressor gene (TSG) in RCC and lung cancer.


SUSD2 RCC Lung cancer Cell proliferation Tumor suppressor gene 



adhesion-associated domain present in MUC4 and other proteins


average rank scores


bone marrow-derived mesenchymal stem/stromal cells


cell counting kit-8


clear cell RCC


differentially expressed genes


gene expression omnibus


gene expression profiles


large cell carcinomas


non-small-cell lung cancer


quantitative RT-PCR


rank-based gene expression


renal cell carcinoma


squamous cell carcinomas


small cell lung cancer


sushi domain containing 2


tumor suppressor gene



This work was supported by the Peking University-National Taiwan University Cooperation Fund (BMU20120316).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Sugahara T, Yamashita Y, Shinomi M, Yamanoha B, Iseki H, Takeda A, et al. Isolation of a novel mouse gene, mSVS-1/SUSD2, reversing tumorigenic phenotypes of cancer cells. Cancer Sci. 2007;6:900–8.CrossRefGoogle Scholar
  2. 2.
    Sugahara T, Yamashita Y, Shinomi M, Isobe Y, Yamanoha B, Iseki H, et al. Von Willebrand factor type D domain mutant of Blackwell Publishing Asia SVS-1/SUSD2, vWD(m), induces apoptosis in HeLa cells. Cancer Sci. 2007;6:909–15.CrossRefGoogle Scholar
  3. 3.
    Watson AP, Evans RL, Egland KA. Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis. Mol Cancer Res. 2013;11:74–85.CrossRefPubMedGoogle Scholar
  4. 4.
    Pan W, Cheng Y, Zhang H, Liu B, Mo X, Li T, et al. CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest. Sci Rep. 2014;4:6812.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Letouzey V, Tan KS, Deane JA, Ulrich D, Gurung S, Ong YR, et al. Isolation and characterisation of mesenchymal Stem/Stromal cells in the ovine endometrium. Plos One. 2015;10:e0127531.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Benz K, Stippich C, Freudigmann C, Mollenhauer JA, Aicher WK, et al. Maintenance of “stem cell” features of cartilage cell sub-populations during in vitro propagation. J Transl Med. 2013;11:27.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ulrich D, Tan KS, Deane J, Schwab K, Cheong A, Rosamilia A, et al. Mesenchymal stem/stromal cells in post-menopausal endometrium. Hum Reprod. 2014;29:1895–905.CrossRefPubMedGoogle Scholar
  8. 8.
    Sivasubramaniyan K, Harichandan A, Schumann S, Sobiesiak M, Lengerke C, Maurer A, et al. Prospective isolation of mesenchymal stem cells from human bone marrow using novel antibodies directed against Sushi domain containing 2. Stem Cells Dev. 2013;22:1944–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Plos One. 2013;8:e62823.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, et al. Basic research in kidney cancer. Eur Urol. 2011;60:622–33.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012;10:859–80.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015;29:1447–62.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J, et al. MiR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther. 2015;8:1773–83.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wang P, Qi H, Song S, Li S, Huang N, Han W, et al. ImmuCo: a database of gene co-expression in immune cells. Nucleic Acids Res. 2015;43:D1133–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang P, Yang Y, Han W, Ma D. ImmuSort, a database on gene plasticity and electronic sorting for immune cells. Sci Rep. 2015;5:10370.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69:5194–201.CrossRefPubMedGoogle Scholar
  21. 21.
    Li T, Cheng Y, Wang P, Wang W, Hu F, Mo X, et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. J Exp Clin Canc Res. 2015;34:122.CrossRefGoogle Scholar
  22. 22.
    Wan Q, Dingerdissen H, Fan Y, Gulzar N, Pan Y, Wu TJ, et al. BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford). 2015. doi: 10.1093/database/bav019.Print2015.Google Scholar
  23. 23.
    Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 2011;50:5566–82.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237:7–13.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Peking University Center for Human Disease Genomics, Department of Immunology, Key Laboratory of Medical Immunology, Ministry of Health, School of Basic Medical SciencesPeking University Health Science CenterBeijingChina
  2. 2.Department of UrologyPeking University People’s HospitalBeijingChina
  3. 3.Department of Thoracic SurgeryBeijing Haidian Hospital (Haidian Section of Peking University Third Hospital)BeijingPeople’s Republic of China
  4. 4.Department of Thoracic SurgeryPeking University People’s HospitalBeijingChina

Personalised recommendations